Lipella Pharmaceuticals Inc. Common Stock Asset Resilience Ratio
Lipella Pharmaceuticals Inc. Common Stock asset resilience ratio. Lipella Pharmaceuticals Inc. Common Stock (LIPO) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Lipella Pharmaceuticals Inc. Common Stoc (LIPO) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lipella Pharmaceuticals Inc. Common Stock (2021–2022)
Asset resilience ratio of Lipella Pharmaceuticals Inc. Common Stock from 2021 to 2022. This chart shows how Lipella Pharmaceuticals Inc. Common Stock's Asset Resilience Ratio has changed over time. Read Lipella Pharmaceuticals Inc. Common Stoc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lipella Pharmaceuticals Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Lipella Pharmaceuticals Inc. Common Stoc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Lipella Pharmaceuticals Inc. Common Stock maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Lipella Pharmaceuticals Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Lipella Pharmaceuticals Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Lipella Pharmaceuticals Inc. Common Stock Asset Resilience Ratio by Year (2021–2022)
Lipella Pharmaceuticals Inc. Common Stock asset resilience ratio by year from 2021 to 2022. The table below shows the annual Asset Resilience Ratio data for Lipella Pharmaceuticals Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $0.00 | $5.95 Million | -- |
| 2021-12-31 | 14.93% | $300.55K | $2.01 Million | -- |
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more